H.C. Wainwright lowered the firm’s price target on Orchestra BioMed (OBIO) to $12 from $14 and keeps a Buy rating on the shares following the Q4 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- OBIO Upcoming Earnings Report: What to Expect?
- Orchestra BioMed initiated with a Buy at BTIG
- Promising Clinical Developments and Strategic Advancements Drive Buy Rating for Orchestra BioMed Holdings
- Orchestra BioMed Highlights Strategic Initiatives and Innovations
- Orchestra BioMed Updates Executive Compensation Policies